Infraredx, Inc., headquartered in Bedford, MA, is a pioneering medical technology company focused on combating Coronary Artery Disease (CAD). The company specializes in advanced imaging systems that utilize Near Infrared Spectroscopy (NIRS) combined with Intravascular Ultrasound (IVUS) to detect vulnerable plaques in coronary arteries. These plaques are fatty deposits that can rupture and cause major adverse cardiac events (MACE) such as heart attacks.

Infraredx's primary product, the NIPRO II Imaging System, is the only FDA-cleared dual-modality catheter and imaging system designed to identify patients and plaques at increased risk of MACE. This technology provides unparalleled insights for cardiologists, enabling them to make more informed decisions about patient care. The company also offers the II Y Connector, a device aimed at reducing blood loss during medical procedures, which is the top-selling Y Connector in Japan and now available in the USA.

Infraredx serves a specialized market of healthcare providers, particularly cardiologists and hospitals, who are focused on the diagnosis and treatment of coronary artery disease. The company's business model revolves around the sale of its imaging systems and related medical devices, as well as providing ongoing support and maintenance services. Revenue is generated through the direct sale of these products and potentially through service contracts for maintenance and support.

In summary, Infraredx is at the forefront of medical technology aimed at improving cardiovascular health. By offering innovative imaging solutions, the company plays a crucial role in the early detection and management of coronary artery disease, ultimately aiming to reduce the incidence of heart attacks and improve patient outcomes.

Keywords: Coronary Artery Disease, Imaging Systems, Near Infrared Spectroscopy, Intravascular Ultrasound, Vulnerable Plaques, FDA-cleared, Cardiology, Medical Devices, Healthcare Providers, Heart Health.